



www.genfit.com

GFT505 BROADENS ITS THERAPEUTIC POTENTIAL

- **New pre-clinical data show that the therapeutic potential of GFT505 covers all the stages of NASH up to cirrhosis and its evolution towards liver cancer.**
- **The underlying mechanism of action opens the door to the evaluation of GFT505 in hepatic/cirrhotic fibrosis linked to chronic viral- or alcohol-induced hepatitis.**
- **The Company has filed a new patent application on the use of GFT505 for treating fibrotic diseases and certain types of cancers.**

Lille (France), Boston (Massachusetts, United States), January 24, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data showing that the therapeutic potential of GFT505 covers all the stages of non-alcoholic steatohepatitis (NASH*) up to cirrhosis and its evolution towards liver cancer.

Studies to date have demonstrated the greater efficacy of GFT505 compared to reference molecules in animal models of hepatic fibrosis. In particular, the daily oral administration of GFT505 not only prevented and blocked the development of fibrosis, but above all favored its elimination. To determine the mechanistic origin of this improvement, GENFIT initiated a major research program to study the anti-fibrotic mechanism of action of GFT505.

The first results shed new light on the therapeutic potential of GFT505 in the advanced stages of chronic fibrotic diseases. In particular, GFT505 could become a treatment for cirrhosis, whether its origin is metabolic, viral, biliary, or linked to alcoholism. Indeed, GFT505 is a strong inhibitor of the proliferation and activation of the cell type responsible for the production of collagen fibers and the extracellular matrix. The underlying molecular mechanism of action suggests the possibility of using GFT505 to treat certain types of cancer, in particular liver cancer.

Commenting on these results, **Dr. Rémy Hanf, EVP, Product Development**, declared: *«These novel findings significantly broaden the therapeutic potential of GFT505 to the advanced stages of chronic hepatitis up to cirrhosis. Considering that even “compensated” cirrhosis can be a life-threatening condition, the importance of this new data is evident. With these results, GENFIT reinforces the innovative character of GFT505 and we have filed a new patent application on the use of GFT505 for treating fibrotic diseases and cancers associated with this new mechanism of action.»*

***About NAFLD/NASH:**

NAFLD (non-alcoholic fatty liver disease) and in particular NASH (non-alcoholic steatohepatitis) are serious liver diseases that can lead to cirrhosis and liver cancer. The development of NAFLD/NASH is associated with the pathophysiological process of insulin resistance in patients that are overweight and/or diabetic. NAFLD is believed to affect 70-80% of diabetic patients, and progresses to chronic liver disease (NASH) in 20-50% of

cases. Mortality due to liver disease is thus 2-3-fold higher in the diabetic population than in the overall population. The NASH market was estimated at 615 \$M in 2010 and should reach 2,008 \$M in 2018.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr